Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than 60 Years Old Ineligible for Standard Induction Chemotherapy

NCT04687761 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT04687761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04687761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than 60 Years Old Ineligible for Standard Induction Chemotherapy
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
November 4, 2020
Completion date
May 30, 2025
Enrollment
113 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

age more 60yr, de novo, leukemia, myeloid, acute